We encourage you to share these materials internally within your company and its affiliates. In accordance with the license granted, however, sharing these materials outside of your organization in any form—electronic, written, or verbal-is prohibited unless you obtain the express, prior, and written consent of Everest Global. Inc. It is your organization's responsibility to maintain the confidentiality of these materials in accordance with your license of them.

Clinical Development Platforms – Vendor Landscape with Products PEAK Matrix® Assessment 2020

September 2020: Complimentary Abstract / Table of Contents

Copyright © 2020 Everest Global, Inc.





Market Life Sciences Report **IT Services**

Our research offerings for global services

► Market Vista™

Global services tracking across functions, sourcing models, locations, and service providers - industry tracking reports also available

Applie	cation Services
BPS	Banking & Financial Services

- BPS | Healthcare & Life Sciences
- BPS | Insurance
- ► Catalyst[™]
- Cloud & Infrastructure
- Customer Experience Management Services
- Contingent Workforce Management
- Data & Analytics
- Digital Services
- Engineering Services
- Enterprise Platform Services

- Finance & AccountingHuman Resources
- ITS | Banking & Financial Services
 ITS | Healthcare
- ITS | Insurance
- ► IT Services Executive Insights[™]
- ► ITS | Life Sciences
- ► Locations Insider™
- ▶ PricePoint[™]
- Procurement
- Recruitment Process Outsourcing
- Service Optimization Technologies

More about membership

In addition to a suite of published research, a membership may include

- Accelerators[™]
- Analyst access
- Data cuts
- Pinnacle Model[®] reports
- PriceBook
- Virtual Roundtables
- Workshops

Custom research capabilities

- Benchmarking | Pricing, delivery model, skill portfolio
- Peer analysis | Scope, sourcing models, locations
- Locations | Cost, skills, sustainability, portfolio plus a tracking tool
- Tracking services | Service providers, locations, risk
- Other | Market intelligence, service provider capabilities, technologies, contract assessment

Membership information

- This report is included in the following research program(s)
 - Life Sciences IT Services (ITS)
- If you want to learn whether your organization has a membership agreement or request information on pricing and membership options, please contact us at <u>info@everestgrp.com</u>

Contents

Introduction and overview 5 1. Research methodology 6 • Key information on the report 7 • Background of the research 8 • Scope of the research 9 2. Clinical development platforms market trends 10 • Clinical trials technology market 11 • Everest Group view of an end-to-end clinical development platform 13 • Buyer challenges to adoption of an end-to-end platform 15 3. Clinical development platforms - products PEAK Matrix® characteristics 17 PEAK Matrix framework 18 • Everest Group PEAK Matrix for clinical development platform vendors 21 • Characteristics of Leaders, Major Contenders, and Aspirants 22 • Product vendor capability summary dashboard 24 4. Everest Group's remarks on clinical development platform vendors 29 30 Accenture • ArisGlobal 31 • BioClinica 32 Bio-Optronics 33 Castor 34

Nitish Mittal, Vice President

Chunky Satija, Practice Director

Nisarg Shah, Senior Analyst

Contents

	CliniOps	35
	Cognizant	36
	Covance	37
	• Datatrak	38
	eClincalHealth	39
	• Ennov	40
	• IBM	41
	• IQVIA	42
	Medidata	43
	Mednet	44
	Navitas Life Sciences	45
	Oracle	46
	Parexel	47
	PRA Health Sciences	48
	• TCS	49
	Veeva Systems	50
5.	Appendix	51
	• Glossary	52
	Research calendar	53



Background of the research

The rising cost of drug development, coupled with increasing regulatory pressures, has led life sciences organizations to rethink the way clinical trials are conducted – the focus is increasingly on failing fast and failing cheap. However, clinical trial challenges, such as siloed data management, delayed timelines due to patient recruitment concerns, and a complex environment of multiple technology solutions, aggravate a pharma organization's woes further. Digital technologies and products have been deployed across the clinical trial landscape to solve for these challenges and bring in efficiencies and automation to reduce manual errors in the process.

Recently, product vendors have started integrating these siloed point solutions into an integrated, modular, and interoperable end-to-end clinical development platform – one platform to address the pharma organization's needs right from study start-up to study closeout. The benefits of a single-platform estate that are claimed include efficient data management, reduced total cost of ownership, and improved visibility of operations. Pharma executives, however, are yet to be convinced about a unified platform approach as they look for success stories and business casing to really move the needle from a best-of-breed approach to a consolidated approach. Everest Group's Clinical Development Platforms – Products PEAK Matrix® Assessment 2020 looks at the current vendor landscape offerings, such platforms, and presents the executive sentiment and insights for such platforms

In this report, we assess the capabilities of 21 IT vendors specific to clinical development platforms and products. These vendors are mapped on the Everest Group PEAK Matrix[®], which is a composite index of a range of distinct metrics related to a vendor's capability and market impact. We focus on:

- Market trends for clinical trials and the associated products market
- The landscape of vendors for clinical trial platforms and products
- Assessment of the vendors on several capability and market success-related dimensions

Scope of this report:








Industry Life sciences (biopharmaceuticals, medical devices, and Contract Research Organizations (CROs))



Vendor offering Clinical development platforms



This report is based on four key sources of proprietary information



Assessments for Bioclinica, Bio-Optronics, Castor, CliniOps, Covance, Datatrak, eClinicalHealth, Ennov, IBM, Navitas Life Sciences, Parexel, PRA Health Sciences, and Veeva Systems excludes product vendor inputs and are based on Everest Group's proprietary Transaction Intelligence (TI) database, product vendor public disclosures, and Everest Group's interactions with pharmaceutical firms that are buyers of clinical development platforms or products The source of all content is Everest Group unless otherwise specified

Confidentiality: Everest Group takes its confidentiality pledge very seriously. Any information we collect that is contract specific will only be presented back to the industry in an aggregated fashion



Scope of the research

In this report, Everest Group focuses on the clinical & pre-clinical trials phase of the life sciences value chain



Building blocks of clinical deve	Building blocks of clinical development systems (Not exhaustive)				
Electronic Data Capture (EDC)	Clinical Trial Management Systems (CTMS)	Randomization and Trial Supply Management (RTSM)	Clinical Data Management (CDM)		
Regulatory systems	Electronic Patient Reported Outcomes (ePRO)	Pharmacovigilance (PV)	Risk-based Monitoring (RBM)		




Overview and abbreviated summary of key messages

This report examines the 2020 clinical development platform vendor landscape and their impact on the clinical development market. It focuses on product vendors position and growth in the clinical development market, changing market dynamics and emerging platform vendor trends, and assessment of platform capabilities

Some of the findings in this report, among others, are:

Clinical development platforms market	 The global clinical trials technology market is expected to grow at 6-8% CAGR over 2019-24, driven by the rise in clinical studies and increase in regulatory and safety standards The overall market opportunity is US\$3 billion (2019) with products and solutions accounting for nearly three-fourths of that pie
Changing market dynamics	 While large ISVs dominate the clinical trial IT market, service providers are trying to establish themselves in this market, with several players bringing forward their own IP e.g. Accenture, Cognizant, and TCS Product vendors are increasingly taking an end-to-end clinical development platform theme to the market, to solve for some challenges. Its modular and interoperable nature enables clients to implement the platform in its entirety or opt for piecemeal implementation of required modules
Emerging service provider trends	 Even though ISVs are trying to pitch for an end-to-end clinical development platform, life sciences enterprises are being change-averse, need more convincing about the value of a unified clinical platform Best of breed approach, lack of success in this space, aversion to rip-and-replace, existing long-term commitments, and interoperability concerns are the major reasons cited for maintaining status quo and not shifting to a single vendor approach
Product vendor delivery capability	 Clinical development platform vendors can be categorized into Leaders, Major Contenders, and Aspirants on a capability-market-share matrix Medidata and Oracle are the current leaders in the clinical development platforms market. However, several product vendors are emerging as major contenders

This study offers four distinct chapters providing a deep dive into key aspects of clinical development platforms market; below are three charts to illustrate the depth of the report



Research calendar Life sciences IT services

Published F

Planned Current release

Flagship Life Sciences IT services reports	Release date
Life Sciences Sales and Marketing Data & Analytics Services PEAK Matrix [®] Assessment 2020	December 2019
Life Sciences State of the Market Report – Trends, Service Provider Performance in 2019, and Outlook for 2020	February 2020
Medical Devices Digital Services PEAK Matrix [®] Assessment 2020	June 2020
Life Sciences Medical Devices Digital Services – State of the Market Report	July 2020
Life Sciences Medical Devices Digital Services – Service Provider Profiles Compendium	July 2020
Clinical Development Platforms – Vendor Landscape with Products PEAK Matrix® Assessment 2020	September 2020
Life Sciences Clinical Development Platforms – State of the Market Report	Q3 2020
Life Sciences Clinical Development Platforms – Vendor Provider Profiles Compendium	Q3 2020
Thematic Life Sciences IT services reports	Release date
Effective Value-Based Contracting in Life Sciences	February 2020
Regulatory Overhaul of the EU Medical Device Market	April 2020
Future Readiness of Life Sciences Enterprise Supply Chains	June 2020
Insourcing in Life Sciences – The Quest for Talent Supremacy	Q3 2020
Intelligent Manufacturing for Life Sciences Enterprises	Q3 2020

Note: For a list of all of our published Life Sciences IT reports, please refer to our website page







Everest Group is a consulting and research firm focused on strategic IT, business services, engineering services, and sourcing. Our clients include leading global enterprises, service providers, and investors. Through our research-informed insights and deep experience, we guide clients in their journeys to achieve heightened operational and financial performance, accelerated value delivery, and high-impact business outcomes. Details and in-depth content are available at **everestgrp.com**.

Stay connected

Website everestgrp.com

Social Media

₩ @EverestGroup

in @Everest Group

- @Everest Group
- @Everest Group

Blog everestgrp.com/blog

Podcast DigitalRealI**T**y

🔞 Listen on Apple Podcasts 🛛 🍃 Google P

Dallas (Headquarters) info@everestgrp.com +1-214-451-3000

Bangalore india@everestgrp.com +91-80-61463500

Delhi india@everestgrp.com +91-124-496-1000 London unitedkingdom@everestgrp.com +44-207-129-1318

New York info@everestgrp.com +1-646-805-4000

Toronto canada@everestgrp.com +1-416-388-6765

This document is for informational purposes only, and it is being provided "as is" and "as available" without any warranty of any kind, including any warranties of completeness, adequacy, or fitness for a particular purpose. Everest Group is not a legal or investment adviser; the contents of this document should not be construed as legal, tax, or investment advice. This document should not be used as a substitute for consultation with professional advisors, and Everest Group disclaims liability for any actions or decisions not to act that are taken as a result of any material in this publication.